Villanova Investment Management Co LLC Purchases 4,217 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Villanova Investment Management Co LLC boosted its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 10.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,224 shares of the life sciences company’s stock after acquiring an additional 4,217 shares during the period. Villanova Investment Management Co LLC owned 0.06% of Integra LifeSciences worth $980,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its position in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares during the period. Empowered Funds LLC purchased a new position in Integra LifeSciences during the 4th quarter valued at about $180,000. Centiva Capital LP bought a new stake in Integra LifeSciences during the third quarter worth about $192,000. Dynamic Technology Lab Private Ltd purchased a new stake in Integra LifeSciences in the third quarter worth about $198,000. Finally, Romano Brothers AND Company bought a new position in shares of Integra LifeSciences during the fourth quarter valued at approximately $204,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $21.99 on Tuesday. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $35.45. The business’s 50-day simple moving average is $23.74 and its two-hundred day simple moving average is $22.24. The stock has a market cap of $1.70 billion, a PE ratio of -244.31, a P/E/G ratio of 0.73 and a beta of 1.23.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $442.65 million for the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter in the previous year, the business posted $0.89 earnings per share. The business’s revenue was up 11.5% compared to the same quarter last year. As a group, analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Morgan Stanley initiated coverage on Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target on the stock. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.